Proxy Votes Now

Home › Funds › Global X › Global X Genomics & Biotechnology ETF

Global X Genomics & Biotechnology ETF (GNOM) proxy voting record 2025-2026

Fund family: Global X · Filed by Global X Funds (CIK 1432353) · SEC series S000062676

Ticker: GNOM (C000203266)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 424 with, 7 against, 0 abstentions (not counted as with management). Shareholder proposals: 5 FOR, 2 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Global X as a whole

The same two figures as Global X’s manager page (125,623 ballot items across 92 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsGlobal XItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)89.9%38891.0%107,427
Backed environmental and social shareholder proposals at US companiesn/a221.0%2,383

Where this fund voted differently from most Global X funds

Each ballot item this fund voted is set against the votes of the other Global X funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Global X funds on all 90 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 78.7% of this fund’s 431 such votes could be given a sector; the other 92 (21.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care31172.3%
Industrials2800.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2370
Audit-related470
Say-on-Pay460
Compensation391
Corporate Governance353
Capital Structure240
Shareholder Rights and Defenses41
Extraordinary Transactions30
Other Social Issues32

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.May 6, 2026$17M50
Moderna, Inc.November 12, 2025$13M20
Illumina, Inc.May 21, 2026$4M110
Guardant Health, Inc.June 17, 2026$4M50
Praxis Precision Medicines, Inc.June 10, 2026$3M50
Natera, Inc.June 11, 2026$3M80
Twist Bioscience CorporationFebruary 5, 2026$3M50
Vertex Pharmaceuticals IncorporatedMay 13, 2026$3M151

Notable votes against management

MeetingCompanyProposalFundMgmt
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalForAgainst
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor

Search this fund’s votes by company

438 ballot items at 51 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Global X Genomics & Biotechnology ETF (GNOM) voted at 51 shareholder meetings of 47 companies, on 438 ballot items in all. Where management made a recommendation, the fund followed it on 98.4% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals less often than Global X's funds as a whole (89.9% against 91.0%). It voted the same way as most Global X funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Global X’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.